查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1854540

按治疗药物、药物类别、类型、最终用户和分销管道分類的老龄化黄斑部病变市场—2025-2032年全球预测

Age-related Macular Degeneration Market by Treatment, Drug Class, Type, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，老龄化黄斑部病变市场规模将达到 189.8 亿美元，复合年增长率为 6.93%。

关键市场统计数据
基准年2024年 111亿美元
预计年份：2025年 118.2亿美元
预测年份 2032 189.8亿美元
复合年增长率 (%) 6.93%

简要概述目前影响老龄化黄斑部病变治疗和策略重点的临床、技术和商业因素。

老龄化黄斑部病变（ 老龄化 ）仍然是眼科研究和临床诊疗的核心，这主要受人口结构变化和治疗方法手段不断发展的推动。 AMD的治疗方法已不再局限于单一治疗方法，而是扩展到生物製药、缓释性製剂、基因疗法和先进影像技术，这给临床医生、支付方和药品生产商带来了复杂的挑战。随着诊断准确性的提高和病患诊疗流程的日益整合，相关人员必须在门诊、医院和专科中心之间协调临床需求与实际运作。

分子生物学和药物递送领域的转化医学进展正在缩短多种治疗层级的研发週期，同时也带来了新的监管和生产挑战。同时，支付方日益严格的审查和采购流程迫使医疗服务提供者优化治疗方法和医疗服务模式。对于决策者而言，了解治疗方法创新、临床应用和供应链韧性之间的相互关係至关重要，这有助于制定永续的策略，在控制医疗总成本的同时，改善可衡量的治疗效果。

本执行摘要整合了整体趋势、供应链动态、市场区隔洞察、区域差异和策略要务，旨在为决策提供基础。其目标是为高层领导者在当今技术创新快速发展和政策主导变革的时代，提供分析严谨且易于理解的基础，帮助他们优先考虑投资、伙伴关係和营运转型。

治疗创新、诊断和数位化医疗路径的整合如何重塑临床实践、商业模式和竞争优势

老龄化黄斑部病变治疗和技术的变革正在深刻地重塑临床路径和供应商策略。抗血管内皮生长因子（VEGF）药物曾是新生血管疾病的标准疗法，如今已与缓释性植入物、可充电给药平台以及旨在减轻治疗负担和提高疗效持久性的新兴基因治疗方法并存。植入的进步，包括更高解析度的光同调断层扫瞄和整合多模态诊断，正在增强疾病分层，并使早期干预成为可能。

人工智慧和云端工作流程正日益广泛地应用于转诊患者的分流、远端监测病情进展以及跨网路标准化治疗决策。这些能力正在改变医疗服务的经济模式，将部分监测活动转移到社区诊所和远端医疗平台，同时将手术介入集中在专科中心。真实世界证据与适应性监管路径的融合加速了创新医疗器材和生技药品的实用化，同时也提高了人们对核准后监测和基于疗效的合约的期望。

因此，商业模式正在不断发展，以适应基于价值的安排、缓释性的差异化定价以及诊断供应商和治疗开发商之间的新伙伴关係——这一格局共同决定了临床疗效、营运效率和竞争格局。

评估2025年美国关税上调对眼科产品供应链、采购行为和策略製造决策的影响

美国2025年关税上调计画对眼科供应链和服务交付产生了连锁的营运和战略影响。进口零件、设备和某些生物製药关税的提高，增加了依赖国际製造地生产管瓶、预填充式注射器、输液系统和专用仪器的供应商的到岸成本。为此，製造商重新评估了其筹资策略，加快了供应商多元化，并优先考虑对其他受託製造厂商进行资格认证，以降低单一国家成本衝击的风险。

医院和专科机构的采购团队开始重新谈判长期供应合同，并要求供应商提高价格透明度，这加大了製造商承受商业性压力，迫使其吸收或抵消关税相关的成本上涨。一些医疗机构考虑调整库存管理，例如增加安全库存和错开采购週期，以应对短期供应中断，但这些调整增加了营运资金和仓储需求。同时，支付方开始更密切地审查报销途径和使用模式，以使报销与整体价值相匹配，并限制关税引发的成本上涨转嫁到最终服务价格上。

关税环境也引发了关于近岸外包和在地化生产能力的讨论，尤其是在可以大规模生产的耗材和医疗设备领域，规模经济效应足以抵销资本投资。然而，监管方面的复杂性和建立国内生产前置作业时间限制了资源调配缓解成本衝击的速度。因此，拥有灵活采购管道、对冲策略和更完善的供应商管治的公司展现出更强的韧性，而上游业务集中度高的公司则面临更大的利润率压力和营运压力。

以细分市场主导的整合洞察，将治疗层级、给药途径、护理环境和分销管道与临床应用和策略机会联繫起来。

市场细分为解读不同治疗方法和通路的临床应用模式和机会提供了一个框架。基于治疗方法的市场分析区分了非药物干预和药物干预，其中非药理学的处置方法进一步细分为雷射疗法和动态疗法。按药物类别划分，区分抗VEGF药物和皮质类固醇，并将抗VEGF药物进一步细分为阿柏西普、Bevacizumab、布罗卢西珠单抗和雷珠单抗，而将皮质类固醇药物细分为地塞米松和曲安奈德，从而清晰地展现了治疗选择、处方动态和标籤主导的用药情况。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 基因疗法治疗干眼症和老龄化黄斑部病变的核准及上市
  • 抗 VEGF 生物相似药可降低治疗成本并扩大患者用药范围。
  • 开发一种缓释性玻璃体内植入，以减少AMD患者的注射频率
  • 将人工智慧演算法应用于老年黄斑部病变的早期诊断和进展监测。
  • 扩展远距眼科平台，为老年黄斑部病变（AMD）管理提供远端监测和虚拟咨询服务
  • 对于老年人而言，个人化的营养和生活方式介入对于减缓老年性黄斑部病变的进展越来越重要。
  • 高解析度视网膜成像技术的进步可更准确地监测黄斑部病变进展

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

老龄化黄斑部病变市场

  • 非药物疗法
    • 雷射治疗
    • 动态疗法
  • 药理学

老龄化黄斑部病变市场

  • 抗 VEGF
    • 阿柏西普
    • Bevacizumab
    • 布罗卢西珠单抗
    • 雷珠单抗
  • 皮质类固醇
    • 地塞米松
    • 曲安奈德

老龄化黄斑部病变市场

  • 干燥
  • 湿的

老龄化黄斑部病变市场

  • 诊所
  • 医院
  • 专业眼科中心

老龄化黄斑部病变市场

  • 医院药房
  • 网路药房
  • 零售药房

老龄化黄斑部病变市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

老龄化黄斑部病变市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

老龄化黄斑部病变市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Regeneron Pharmaceuticals, Inc.
    • Bayer AG
    • Novartis AG
    • F. Hoffmann-La Roche AG
    • Alcon Inc.
    • Carl Zeiss AG
    • Topcon Healthcare, Inc.
    • Nidek Co., Ltd.
    • Heidelberg Engineering GmbH
    • Optos plc
Product Code: MRR-F927BA46233D

The Age-related Macular Degeneration Market is projected to grow by USD 18.98 billion at a CAGR of 6.93% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 11.10 billion
Estimated Year [2025] USD 11.82 billion
Forecast Year [2032] USD 18.98 billion
CAGR (%) 6.93%

A concise orientation to current clinical, technological, and operational forces reshaping age-related macular degeneration care and strategic priorities

Age-related macular degeneration remains a central focus for ophthalmic research and clinical care, driven by demographic shifts and evolving therapeutic possibilities. The landscape has expanded beyond single-modality treatments to encompass biologics, sustained-release devices, gene-based interventions, and advanced imaging, creating a complex environment for clinicians, payers, and manufacturers to navigate. As diagnostic precision improves and patient pathways become more integrated, stakeholders must reconcile clinical need with operational realities across outpatient clinics, hospitals, and specialty centers.

Translational advances in molecular biology and drug delivery have shortened development cycles for some therapeutic classes while introducing new regulatory and manufacturing challenges. Concurrently, payer scrutiny and procurement practices have intensified, prompting providers to optimize treatment regimens and care delivery models. For decision-makers, understanding the interplay between therapeutic innovation, clinical adoption, and supply chain resiliency is essential to formulate sustainable strategies that deliver improved visual outcomes while controlling total cost of care.

This executive summary synthesizes prevailing trends, supply chain dynamics, segmentation insights, regional nuances, and strategic imperatives to enable informed action. The intent is to offer an analytically rigorous yet accessible foundation for senior leaders seeking to prioritize investments, partnerships, and operational changes in the current era of rapid technological and policy-driven shifts.

How converging therapeutic innovations, diagnostics, and digital care pathways are redefining clinical practice, commercial models, and competitive advantage

The therapeutic and technological shifts occurring in age-related macular degeneration are reshaping clinical pathways and vendor strategies in meaningful ways. Anti-VEGF agents, which once defined the standard of care for neovascular disease, now coexist with sustained-release implants, refillable delivery platforms, and emerging gene-based modalities that aim to reduce treatment burden and improve durability. Imaging advances, including higher-resolution optical coherence tomography and integrated multimodal diagnostics, have enhanced disease stratification and enabled earlier interventions.

Artificial intelligence and cloud-enabled workflows are increasingly used to triage referrals, monitor progression remotely, and standardize treatment decision-making across networks. These capabilities are altering care delivery economics by shifting some monitoring activities to community clinics and telemedicine platforms while concentrating procedural interventions within specialty centers. The convergence of real-world evidence and adaptive regulatory pathways has accelerated the translation of innovative devices and biologics, but it has also amplified expectations for post-approval surveillance and outcome-based contracting.

As a result, commercial models are evolving to accommodate value-based arrangements, differentiated pricing for sustained-delivery products, and new partnerships between diagnostic vendors and therapeutic developers. The cumulative effect is a landscape in which clinical effectiveness, operational efficiency, and commercial agility collectively determine competitive positioning.

Assessment of how 2025 tariff escalations in the United States disrupted ophthalmic supply chains, procurement behavior, and strategic manufacturing decisions

The imposition of elevated tariff measures in the United States during 2025 has created a cascade of operational and strategic consequences for the ophthalmic supply chain and service delivery. Higher duties on imported components, devices, and certain biologic inputs elevated landed costs for suppliers who rely on international manufacturing hubs for vials, prefilled syringes, delivery systems, and specialized instrumentation. In response, manufacturers reassessed sourcing strategies, accelerated supplier diversification, and prioritized qualification of alternative contract manufacturing organizations to reduce exposure to single-country cost shocks.

Procurement teams within hospitals and specialty centers began to renegotiate long-term supply agreements and to demand greater price transparency from vendors, which intensified commercial pressure on manufacturers to absorb or offset tariff-related cost increases. Some providers explored changes in inventory management, such as larger safety stocks or staggered purchasing cycles, to buffer against short-term disruption, but these adjustments increased working capital requirements and warehousing needs. In parallel, payers scrutinized reimbursement pathways and utilization patterns more closely, seeking to align reimbursement with overall value and to limit the transference of tariff-induced cost inflation to final service pricing.

The tariff environment also catalyzed conversations about nearshoring and localized production capacity, particularly for high-volume consumables and delivery devices, where scale economics could justify capital investments. Regulatory interplay and lead times for establishing domestic manufacturing, however, constrained the speed at which reshoring could mitigate cost impacts. Consequently, companies that adopted flexible sourcing, hedging strategies, and stronger supplier governance demonstrated greater resilience, while those with concentrated upstream exposure experienced amplified margin pressure and operational strain.

Integrated segmentation-driven insights linking therapeutic classes, delivery pathways, care settings, and distribution channels to clinical adoption and strategic opportunity

Segmentation provides a framework to interpret clinical adoption patterns and commercial opportunity across distinct therapeutic and distribution pathways. Based on Treatment, market analysis differentiates Non-Pharmacological modalities and Pharmacological interventions, with Non-Pharmacological approaches further situated within Laser Therapy and Photodynamic Therapy; this structure highlights where minimally invasive procedural options intersect with drug-based approaches. Based on Drug Class, the analytical lens distinguishes Anti-VEGF agents from Corticosteroids, and further dissects Anti-VEGF into Aflibercept, Bevacizumab, Brolucizumab, and Ranibizumab while categorizing Corticosteroids into Dexamethasone and Triamcinolone, enabling a clear view of therapeutic substitution, formulary dynamics, and label-driven usage.

Based on Type, the segmentation separates Dry and Wet disease pathways to emphasize differences in disease progression, unmet need, and potential for regenerative or complement-targeted strategies. Based on End User, the analysis considers Clinics, Hospitals, and Specialty Ophthalmic Centers as distinct channels of care delivery, each with unique procurement, staffing, and capacity characteristics that shape technology adoption and treatment frequency. Based on Distribution Channel, the study assesses Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy pathways to reflect evolving purchasing behaviors, the rise of digital dispensing models, and implications for cold-chain logistics and patient access.

Together, these segmentation dimensions allow for nuanced interpretation of clinical utilization patterns, capital and operating investment priorities, and the differential impact of policy or reimbursement changes across care settings. By mapping therapeutic innovations to end-user and distribution realities, stakeholders can better anticipate adoption bottlenecks and prioritize interventions that address the most consequential frictions.

Regional nuances in clinical adoption, regulatory pathways, and commercialization approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics continue to shape clinical practice patterns, regulatory expectations, and commercialization strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established reimbursement systems and high adoption rates of intravitreal therapies have driven an emphasis on treatment optimization, adherence strategies, and innovations that reduce visit frequency; provider consolidation and integrated delivery networks have also influenced procurement and contracting behavior. Across Europe, Middle East & Africa, heterogeneous regulatory pathways and payer models have led manufacturers to pursue localized evidence generation and adaptive pricing arrangements to secure formulary inclusion and maintain profitability.

In the Asia-Pacific region, rapid investment in diagnostic infrastructure, growing clinical trial activity, and increasing demand from aging populations have accelerated uptake of next-generation therapeutics, while a focus on manufacturing scale and cost optimization has made the region central to global supply networks. Cross-region collaboration, such as multinational clinical programs and harmonized regulatory submissions, has become more common as developers seek to shorten time-to-market and align safety monitoring across jurisdictions. Variations in healthcare infrastructure and provider distribution also affect where procedural capacity is concentrated, often requiring differentiated commercial and training strategies for specialty centers versus community clinics.

Understanding these regional nuances is critical for designing phased market entry plans, aligning regulatory dossiers with local evidence needs, and developing channel strategies that reflect payer expectations and provider capabilities within each geography.

Strategic corporate behaviors and partnership models shaping therapeutic leadership, delivery innovations, and integrated offerings in the AMD ecosystem

Corporate strategy in the age-related macular degeneration ecosystem is characterized by a mix of portfolio diversification, targeted partnerships, and investments in advanced manufacturing and data capabilities. Established biopharmaceutical sponsors maintain leadership through iterative improvements to licensed anti-VEGF agents and by sponsoring real-world evidence studies to support label expansions and dosing innovations. Simultaneously, companies with niche capabilities in sustained-delivery systems and ocular devices are leveraging strategic alliances to combine delivery platforms with established biologics, creating differentiated offerings that address clinician and patient demand for reduced treatment burden.

Across the competitive landscape, alliances between therapeutic developers, contract manufacturers, and diagnostic vendors have increased, reflecting a recognition that integrated solutions-combining therapy, monitoring, and adherence tools-provide stronger commercial value propositions. Investment activity has favored firms that can demonstrate scalable aseptic manufacturing, robust cold-chain logistics, and regulatory experience in ophthalmic modalities. Additionally, firms pursuing novel mechanisms for geographic atrophy and complement inhibition have attracted attention from investors and partners, underscoring the broader appetite for first-in-class interventions within dry AMD.

Companies that prioritize interoperable data strategies, regulatory planning for global submissions, and flexible commercial models for diverse payer environments are better positioned to capture opportunities. At the same time, market entrants must navigate pricing scrutiny and evidentiary expectations, making strategic collaborations and selective evidence generation crucial to commercial success.

Practical and prioritized strategic actions executives should implement to strengthen clinical value, supply resilience, market access, and commercial differentiation

Industry leaders should pursue a set of pragmatic actions to align clinical value with commercial sustainability and operational resilience. First, prioritize development of durable delivery mechanisms and combination approaches that demonstrably reduce treatment frequency while preserving or enhancing long-term visual outcomes; evidence packages should emphasize patient-centric endpoints and health system resource utilization. Second, strengthen supply chain flexibility by qualifying multiple manufacturing partners across geographies and by investing in inventory analytics that reduce lead-time risk while controlling working capital demands.

Third, implement differentiated market access strategies that tailor evidence generation to regional payer expectations and to the specific needs of clinics, hospitals, and specialty centers. This includes negotiation-ready value propositions that reflect real-world treatment pathways and potential savings from reduced visit burden. Fourth, embed digital and diagnostic partnerships into commercial plans to support remote monitoring, adherence programs, and outcome tracking, thereby improving post-launch data collection and enabling outcome-based contracting where feasible. Fifth, foster cross-functional alignment between regulatory, clinical, and commercial teams to streamline global submissions and coordinate post-approval safety monitoring, which will accelerate adoption while maintaining compliance.

Taken together, these actions reduce operational exposure, enhance provider and patient value, and create defensible differentiation in a competitive therapeutic landscape. Executives should sequence investments to balance near-term revenue protection with mid- to long-term capability building that supports sustained leadership.

A robust mixed-methods research framework integrating primary stakeholder interviews, secondary regulatory and clinical evidence, and scenario validation for actionable intelligence

The research approach combined primary qualitative inquiry with comprehensive secondary evidence review to ensure robustness and practical relevance. Primary research included structured interviews with ophthalmologists, procurement leads in hospitals and specialty centers, senior commercial executives, and clinical trial investigators to capture frontline perspectives on treatment adoption, operational constraints, and payer interactions. Secondary sources encompassed peer-reviewed clinical literature, regulatory approval documents, clinical trial registries, and public filings to validate therapeutic profiles, indications, and safety data.

Data synthesis involved cross-validation of interview insights with published evidence and regulatory summaries, supplemented by scenario analysis to explore operational and policy contingencies such as tariff changes or shifts in reimbursement. Segmentation frameworks were developed by mapping therapeutic modalities, drug classes, disease subtypes, end-user settings, and distribution channels to clinical workflows and procurement pathways. Quality assurance measures included reconciliation of conflicting sources, iterative expert review, and transparent documentation of assumptions and inclusion criteria.

Limitations of the methodology include variability in regional reporting standards and the evolving nature of clinical trial outcomes, which necessitates ongoing monitoring of late-stage data. Nonetheless, the triangulated approach provides a reliable foundation for strategic decision-making by integrating real-world clinician perspectives with rigorous secondary evidence and disciplined analytical techniques.

Concluding synthesis linking clinical innovation, operational preparedness, and strategic imperatives required to realize improved outcomes in age-related macular degeneration

In sum, the age-related macular degeneration landscape is at an inflection point where therapeutic innovation, delivery technologies, and systemic pressures intersect to reshape care paradigms. Advances that reduce treatment frequency or address unmet needs in dry AMD offer meaningful clinical promise, but their realization depends on coordinated evidence generation, adaptive commercial models, and resilient supply chains. Stakeholders who proactively adapt procurement practices, invest in manufacturing agility, and align evidence strategies with payer expectations will be better equipped to translate scientific breakthroughs into sustainable clinical and commercial value.

Operationally, the capacity to integrate diagnostics, digital monitoring, and adherence solutions into product offerings will influence adoption trajectories and payer receptivity. Strategically, selective partnerships and targeted regional approaches enable sponsors to balance the demands of regulatory heterogeneity and localized payer systems. As the landscape continues to evolve, ongoing vigilance, flexible planning, and a focus on measurable patient benefit will be essential to converting innovation into improved outcomes across diverse care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Approval and market adoption of gene therapy approaches for dry age-related macular degeneration
  • 5.2. Emergence of anti-VEGF biosimilars reducing treatment costs and expanding patient access
  • 5.3. Development of sustained-release intravitreal implants to reduce injection frequency in AMD patients
  • 5.4. Integration of artificial intelligence algorithms for early diagnosis and progression monitoring of AMD
  • 5.5. Expansion of teleophthalmology platforms to deliver remote monitoring and virtual consultations for AMD management
  • 5.6. Growing emphasis on personalized nutrition and lifestyle interventions to slow AMD progression in aging populations
  • 5.7. Advancements in high-resolution retinal imaging devices for more precise monitoring of macular degeneration progression

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Age-related Macular Degeneration Market, by Treatment

  • 8.1. Non-Pharmacological
    • 8.1.1. Laser Therapy
    • 8.1.2. Photodynamic Therapy
  • 8.2. Pharmacological

9. Age-related Macular Degeneration Market, by Drug Class

  • 9.1. Anti-Vegf
    • 9.1.1. Aflibercept
    • 9.1.2. Bevacizumab
    • 9.1.3. Brolucizumab
    • 9.1.4. Ranibizumab
  • 9.2. Corticosteroid
    • 9.2.1. Dexamethasone
    • 9.2.2. Triamcinolone

10. Age-related Macular Degeneration Market, by Type

  • 10.1. Dry
  • 10.2. Wet

11. Age-related Macular Degeneration Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Specialty Ophthalmic Centers

12. Age-related Macular Degeneration Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Age-related Macular Degeneration Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Age-related Macular Degeneration Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Age-related Macular Degeneration Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Regeneron Pharmaceuticals, Inc.
    • 16.3.2. Bayer AG
    • 16.3.3. Novartis AG
    • 16.3.4. F. Hoffmann-La Roche AG
    • 16.3.5. Alcon Inc.
    • 16.3.6. Carl Zeiss AG
    • 16.3.7. Topcon Healthcare, Inc.
    • 16.3.8. Nidek Co., Ltd.
    • 16.3.9. Heidelberg Engineering GmbH
    • 16.3.10. Optos plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. AGE-RELATED MACULAR DEGENERATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AGE-RELATED MACULAR DEGENERATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMA